Bilast oral solution (Bilastine)

• Composition :
  Each ml of oral solution contains Bilastine 2.5mg
• Indications :
  Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria
• Pharmacodynamics :
  Bilastine is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. It shows moderate to high affinity for histamine H1-receptors and no affinity for muscarinic, serotonergic, dopaminergic and noradrenergic receptors.
• Dosage and administration :
  The recommended dose in children 6 to 11 years of age with a body weight of at least 20 kg is 10 mg bilastine (4 ml of oral solution) once daily for the relief of symptoms of allergic rhinoconjunctivitis and urticaria.
• Contraindications :
  Hypersensitivity to bilastine or to any ingredient in the formulation or component.
• Precautions and warnings :
  Coadministration of bilastine and P-glycoprotein inhibitors should be avoided in patients with moderate or severe renal impairment.
• Use in pregnancy, lactation & pediatrics :
  There are no or limited amount of data from the use of bilastine in pregnant women. The excretion of bilastine in milk has not been studied in humans. A decision on whether to discontinue/abstain from bilastine therapy must be made taking into account the benefit of breast-feeding for the child and mother. Efficacy and safety of bilastine in children under 2 years of age have not been established and there is little clinical experience in children aged 2 to 5 years, therefore bilastine should not be used in these age groups.
• Drug interactions :
  Concomitant intake of bilastine 20 mg o.d. and ketoconazole 400 mg o.d. or erythromycin 500 mg t.i.d. increased plasma concentration of bilastine
• Adverse reactions :
  The most commonly reported adverse events are headache, somnolence, dizziness, and fatigue.
• Therapy Area :
  Anti-Allergics